Massachusetts-based gene-editing startup Beam Therapeutics has dosed its first patient in a Phase I/II clinical trial with BEAM-201, a quadruplex base-edited allogeneic chimeric antigen receptor T (CAR-T)-cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia/T-cell lymphoblastic lymphoma (T-ALL/T-LL).
The T-ALL/T-LL patient is reportedly the company’s first patient to be dosed with its drug candidate and the first patient in the US to undergo a base editing therapy. The patient enrollment for the Phase I/II clinical trial for BEAM-201 is ongoing across several sites.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.